PROTHENA CORPORATION PUBLIC LIMITED COMPANY Current Assets
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) had Current Assets of $292.01 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $292.01M.
- 2026-03-31: Assets, Current $339.20M.
- 2025-12-31: Assets, Current $315.19M.
- 2025-09-30: Assets, Current $339.97M.
| Period end | Assets, Current | Assets, Current as first filed |
|---|---|---|
| 2026-06-30 | $292.01M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $339.20M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $315.19M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $339.97M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $385.48M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $436.17M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $485.41M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $534.98M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $585.98M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $565.87M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $639.28M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $690.60M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $677.10M 10-Q · filed 2023-08-03 | |
| 2023-03-31 | $700.34M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $719.10M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $524.56M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $521.29M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $555.62M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $584.81M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $607.53M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $409.47M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $352.30M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $299.28M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $320.49M 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $341.12M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $359.69M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $378.38M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $409.20M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $418.71M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $415.19M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $431.39M 10-K · filed 2020-03-03 | |
| 2018-09-30 | $456.91M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $494.04M 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $537.15M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $426.33M 10-K · filed 2019-03-15 | |
| 2017-09-30 | $469.06M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $511.72M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $514.20M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $391.36M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $415.64M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $450.60M 10-Q · filed 2016-08-02 | |
| 2016-03-31 | $482.09M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $377.40M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $393.58M 10-Q · filed 2015-11-02 | |
| 2015-06-30 | $406.20M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $284.42M 10-Q · filed 2015-05-06 | |
| 2014-12-31 | $299.11M 10-K · filed 2016-02-25 | $299.27M 10-K · filed 2015-03-13 |
| 2014-09-30 | $308.82M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $307.02M 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $199.60M 10-Q · filed 2014-05-05 | |
| 2013-12-31 | $178.22M 10-K · filed 2015-03-13 | |
| 2013-09-30 | $102.94M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $113.59M 10-Q · filed 2013-08-13 | |
| 2013-03-31 | $120.79M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $125.84M 10-K · filed 2014-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |